Ubs Oconnor LLC Tg Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 20,000 shares of TGTX stock, worth $617,000. This represents 0.03% of its overall portfolio holdings.
Number of Shares
20,000Holding current value
$617,000% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding TGTX
# of Institutions
338Shares Held
88.3MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$475 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$351 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$281 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$111 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$98.9 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.48B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...